Direct thrombin inhibitors for the prevention of venous thromboembolism after major orthopaedic surgery

Current Pharmaceutical Design

Volumn 11, Issue 30, 2005, Pages 3885-3891

  Agnelli, Giancarlo ^a   Sonaglia, Francesco ^a   Becattini, Cecilia ^a  

^a UNIVERSITY OF PERUGIA   (Italy)

Author keywords

Direct antithrombins; Hirudin; Major orthopaedic surgery; Melagatran; Pulmonary embolism; Venous thromboembolism; Ximelagatran

Indexed keywords

ANTICOAGULANT AGENT; ANTIVITAMIN K; ARGATROBAN; ARGIDIPINE; DABIGATRAN ETEXILATE; DALTEPARIN; DESULFATOHIRUDIN; EFEGATRAN; ENOXAPARIN; FIBRIN; HEPARIN; HIRUDIN; HIRUGEN; HIRULOG; INOGATRAN; LEPIRUDIN; LOW MOLECULAR WEIGHT HEPARIN; MELAGATRAN; NAPSAGATRAN; THROMBIN; THROMBIN INHIBITOR; UNCLASSIFIED DRUG; WARFARIN; XIMELAGATRAN;

BLEEDING; CLINICAL TRIAL; DEEP VEIN THROMBOSIS; DRUG BLOOD LEVEL; DRUG DOSE REGIMEN; DRUG HALF LIFE; DRUG HYPERSENSITIVITY; DRUG SYNTHESIS; ENZYME INHIBITION; HEART ATRIUM FIBRILLATION; HEART MUSCLE ISCHEMIA; HIGH RISK PATIENT; HUMAN; ORTHOPEDIC SURGERY; PRIORITY JOURNAL; PROTEIN BINDING; REVIEW; STROKE; THROMBOSIS; VENOUS THROMBOEMBOLISM;

ANIMALS; FIBRINOLYTIC AGENTS; HUMANS; ORTHOPEDIC PROCEDURES; POSTOPERATIVE COMPLICATIONS; THROMBIN; THROMBOEMBOLISM;

EID: 27744464296     PISSN: 13816128     EISSN: None     Source Type: Journal    
DOI: 10.2174/138161205774580615     Document Type: Review

References (52)

1. Verstraete M. Heparin in the prevention and treatment of arterial thromboembolism. Adv Exp Med Biol 1992; 313: 249-258.
2. Hirsh J. Heparin. N Engl J Med 1991: 324: 1565-1574.
3. Hogg PJ, Jackson CM. Fibrin monomers protects thrombin from inactivation by heparin/antithrombin III: implications for heparin efficacy. Proc Nad Acad Sci USA 1989; 86: 3619-3623.
4. Weitz JI, Hudoba M, Massel D, Maraganore J, Hirsh J. Clot bound thrombin is protected from inhibition by heparin/antithrombin III but is susceptible to inactivation by antithrombin III independent inhibitors. J Clin Invest 1990; 86: 385-391.
5. Bar-Shavit R, Benezra M, Eldor A, Hy-Am E, Fenton JW 2nd, Wilner GD, et al. Thrombin immobilized to extracellular matrix is a potent mitogen for vascular smooth muscle cells: non enzymatic mode of action. Cell Regulation 1990; 1: 453-463.
6. Alving BM, Krishnamutri C. Recognition and management of heparin-induced thrombocytopenia (HIT) and thrombosis. Semin Thromb Haemost 1997; 23: 569-574.
7. Warkentin TE, Levine MN, Hirsh J, Horsewood P, Roberts RS, Gent M, et al. Heparin-induced thrombocytopenia in patients treated with low-molecular heparin or unfractionated heparin. N Engl J Med 1995; 332: 1330-1335.
8. Nurmohamed MT, Rosendaal FF, Büller HR, et al. Low molecular weight heparin versus standard heparin in general and orthopedic surgery: a meta-analysis. Lancet 1992; 340: 152-156.
9. Leizorovicz A, Haugh MC, Chapuis FR Samama NW, Boissel JP. Low molecular weight heparin in the prevention of peri-operative thrombosis. Brit Med J 1992; 305: 913-920.
10. Hirsh J. Oral anticoagulants. N Engl J Med 1991; 324: 1865-1875.
11. Krstenansky, JL, Mao SJT. Antithrombin properties of C-terminus of hirudin using synthetic unsulfated N α-acetyl-hirudin 45-65. FEBS Lett 1987; 211:10-16.
12. Maraganore JM, Chao B, Joseph ML, Jablonski J, Ramachandran KL. Anticoagulant activity of synthetic hirudin fragments J Biol Chem 1989; 264: 8692-8698.
13. Gustafsson D, Antonsson T, Bylund R, Eriksson U, Gyzander E, Nilsson I, et al. Effects of melagatran, a new low molecular weight thrombin inhibitor, on thrombin and fibrinolytic; enzymes. Thromb Haemost 1998; 79: 110-118.
14. Hauel NH, Nar H, Priepke H, Ries U, Stassen JM, Wienen W. Structure-based design of novel potent nonpeptide thrombin inhibitors. J Med Chem 2002; 45: 1757-66.
15. Kikumoto R, Tamao Y, Tezuka T, Tonomura S, Hara H, Ninomiya K, et al. Selective inhibition of thrombin by (2R-4R)-4-methyl-1 [N-[(3-methyl-1,2,3,4-tetrahydro 8-quinolinyl) sulfanyl]-L-arginyl]-2-piperidine carboxylic acid. Biochemistry 1984; 23: 85-90.
16. Gast A, Tschopp TB, Baumgartner HR. Thrombin plays a key role in platelet thrombus growth and/or stability. Effect of a specific thrombin inhibitor on thrombogenesis induced by aortic subendothelium exposed to flowing rabbit blood. Arterioscl Thromb 1994; 14: 1466-1474.
17. Teger-Nilsson AC, Gyzander E, Andersson S, et al. In vitro properties of inogatran, a new selective low molecular weight inhibitor of thrombin. Thromb Haernost 1995; 73: 1325.
18. 4. Thromb Haemost 1992; 67: 325-330.
19. Petersen TE, Roberts HR, Sottrup-Jensen L, Magnussov S. Primary structure of hirudin, a thrombin specific inhibitor. In: Peters H, ed. Peptides of the biological fluids. Oxford: Pergamon 1976; 145-149.
20. Stone SR, Hofsteenge J. Kinetics of inhibition of thrombin by hirudin. Biochemistry 1986; 25: 4622-4628.
21. Parry MA, Maraganore M, Stone SR. Kinetic mechanism for the interaction of hirulog with thrombin. Biochemistry 1994; 33: 14807-14814.
22. Tamao Y, Yamamoto T, Hirata T, et al. Effect of argidipine (MD-805) on blood coagulation. Jpn Pharmacol Ther 1986; 14: 869-874.
23. Hilpert K, Ackermann J, Banner DW, Gast A, Gubernator K, Hadvary P, et al. Design and synthesis of potent and highly selective thrombin inhibitors. J Med Chem 1094; 37: 3889-3901.
24. Smith GF, Shuman RT, Craft TJ, Gifford DS, Kurz KD, Jones ND, et al. A family of arginal thrombin inhibitors related to efegatran. Semin Thromb Haemost 1996; 22:173-183.
25. Hauptmann J, Sturzebecher J. Synthetic inhibitors of thrombin and factor Xa: from bench to bedside.Thromb Res 1999, 93: 203-241.
26. Verstraete M, Nurmohamed M, Kienast J, Siebeck M, Silling-Engelhardt G, Buller H, et al. Biologic effects of recombinant hirudin (CGP 39393) in human volunteers. J Am Coll Cardiol 1993; 22: 1080-1088.
27. Lefevre G, Duval M, Gauron S, Brookman LJ, Rolan PE, Morris TM, et al. Effect of renal impairment on the pharmacokinetics and pharmacodynamics of desirudin. Clin Pharmacol Ther 1997; 62: 50-59.
28. Meyer BH, Luus HG, Müller FO, Badenhoerst PN, Röthig HJ. The pharmacology of recombinant hirudin, a new anticoagulant. S Afr Med 1990; 78: 268-270.
29. Fox I, Dawson A, Loynds P, Eisner J, Findlen K, Levin, E, et al. Anticoagulant activity of hirulog™, a direct thrombin inhibitor, in humans. Thromb Haemost 1993; 69:157-163.
30. Gustafsson D, Nystrom J, Carlsson S, Bredberg U, Eriksson U, Gyzander E, et al. The direct thrombin inhibitor Melagatran and its oral prodrug H376/95: intestinal absorption properties, biochemical and pharmacodynamic effects. Thromb Res 2001; 101: 171-181.
31. Mungall D. BIBR-1048 Boehringer Ingelheim. Curr Opin Investig Drugs 2002; 3: 905-7.
32. Geerts WH, Heit JA, Clagett GP, Pineo GF, Colwell CW, Anderson FA Jr, et al. Prevention of venous thromboembolism. Chest 2001; 119(suppl 1): 132S-175S.
33. Eriksson BI, Kalebo P, Ekman S, Lindbratt S, Kerry R, Close P. Direct thrombin inhibition with rec-hirudin CGP 39393 as prophylaxis of thromboembolic complications after total hip replacement. Thromb Haemost 1994; 72: 227-231.
34. Eriksson BI, Ekman S, Kalebo P, Zachrisson B, Bach D, Close P. Prevention of deep vein thrombosis after total hip replacement: direct thrombin inhibition with recombinant Hirudin, CGP 39393. Lancet 1996; 347: 635-639.
35. Eriksson BI, Ekman S, Lindbratt S, Baur M, Bach D, Torholm C, et al. Prevention of thromboembolism with use of recombinant hirudin. Results of a double-blind, multicenter trial comparing the efficacy of desirudin (Revasc) with that of unfractionated heparin in patients having a total hip replacement. J Bone Joint Surg Am 1997; 79: 326-33.
36. Eriksson BI, Wille-Jorgensen P, Kalebo P, Mouret P, Rosencher N, Bosch P, et al. A comparison of recombinant hirudin with a low-molecular-weight heparin to prevent thromboembolic complications after total hip replacement. N Engl J Med 1997; 337: 1329-35.
37. Ginsberg JS, Nurmohamed MT, Gent M, MacKinnon B, Sicurella J, Brill-Edwards P, et al. Use of hirulog in the prevention of venous thrombosis after major hip or knee surgery. Circulation 1994; 90: 2385-2389.
38. Eriksson BI, Arfwidsson AC, Frison L, Eriksson UG, Bylock A, Kalebo P, et al. A dose-ranging study of the oral direct thrombin inhibitor, ximelagatran, and its subcutaneous form, melagatran, compared with dalteparin in the prophylaxis of thromboembolism after hip or knee replacement. METHRO I: Melagatran for Thrombin inhibition in Orthopedic surgery. Thromb Haemost 2002; 87: 231-7.
39. Eriksson BI, Bergqvist D, Kalebo P, Dahl OE, Lindbratt S, Bylock A, et al. Melagatran for Thrombin inhibition in Orthopaedic surgery. Ximelagatran and melagatran compared with dalteparin for prevention of venous thromboembolism after total hip or knee replacement: the METHRO II randomised trial. Lancet 2002; 360:1441-7.
40. Eriksson BI, Agnelli G, Cohen AT, Dahl OE, Mouret P, Rosencher N, et al. Direct thrombin inhibitor melagatran followed by oral ximelagatran in comparison with enoxaparin for prevention of venous thromboembolism after total hip or knee replacement. Thromb Haemost 2003; 89:288-96.
41. Eriksson BI, Agnelli G, Cohen AT, Dahl OE, Lassen MR, Mouret P, et al. on behalf of the Express Study Group. The direct thrombin inhibitor melagatran followed by oral ximelagatran compared with enoxaparin for the prevention of venous thromboembolism after total hip or knee replacement. the Express study. J Thromb Haemost 2003; 1: 2490-6.
42. Heit JA, Colwell CW, Francis CW, Ginsberg JS, Berkowitz SD, Whipple J, et al. Comparison of the oral direct thrombin inhibitor ximelagatran with enoxaparin as prophylaxis against venous thromboembolism after total knee replacement. A phase 2 dose-finding study. Arch Intern Med 2001; 161: 2215-2221.
43. Francis CW, Davidson BL, Berkowitz SD, Lotke PA, Ginsberg JS, Lieberman JR, et al. Ximelagatran versus warfarin for the prevention of venous thromboembolism after total knee arthroplasty. A randomized, double-blind trial. Ann Intern Med 2002; 137: 648-55.
44. Peters GR, Roth AW, McElhattan J, Colwell CW Jr. EXULT A Study Group. Comparison of ximelagatran with warfarin for the prevention of venous thromboembolism after total knee replacement. N Engl J Med 2003; 349:1703-12.
45. Colwell CW, Berkowitz SD, Comp PC, Lieberman JL, Ginsberg JS, Paiement G, et al. Randomized, double blind comparison of Ximelagatran, an oral direct thrombin inhibitor, and warfarin to prevent venous thromboembolism (VTE) after total knee replacement. Blood 2003; 102: abstract 39.
46. Colwell CW Jr, Berkowitz SD, Davidson BL, Lotke PA, Ginsberg JS, Lieberman JR, et al. Comparison of ximelagatran, an oral direct thrombin inhibitor, with enoxaparin for the prevention of venous thromboembolism following total hip replacement. A randomized, double-blind study. J Thromb Haemost 2003; 1: 2119-2130.
47. Eriksson BI, Dahl OE, Ahnfelt L, Kalebo P, Stangier J, Nehmiz G, et al. Dose escalating safety study of a new oral direct thrombin inhibitor, dabigatran etaxilate, in patients undergoing total hip replacement: BISTRO- 1. J Thomb Haemost 2004; 2: (in press).
48. Eriksson BI, Dahl OE, Buller HR, Hettiarachchi R, Rosencher N, Bravo ML, et al. Dabigatran etexilate, new oral direct thrombin inhibitor, in the prevention of thromboembolic events after total hip/knee replacement: BISTRO-2 study. Pathophysiol Haemost Thromb 2004; 33: 38.
49. Dahl OE, Eriksson BI, Buller HR, Hettiarachchi R, Rosencher N, Bravo ML, el al. Timing of initiation of thromboembolism prophylaxis in total hip/knee replacement with dabigatran etexilate, a new oral direct thrombin inhibitor. Pathophysiol Haemost Thromb 2004; 33: 39.
50. Casu B, Guerrini M, Torri G. Structural and conformational aspects of the anticoagulant and anti-thrombotic activity of heparin and dermatan sulfate. Curr Pharm Design 2004; 10(9): 939-49.
51. Gruber A, Hanson SR. Potential new targets for antithrombotic therapy. Curr Pharm Design 2003; 9(28): 2367-74.
52. Nader HB, Lopes CC, Rocha HA, Santos EA, Dietrich CP. Heparins and heparinoids: occurrence, structure and mechanism of anti-thrombotic and hemorrhagic activities. Curr Pharm Design 2004. 10(9):951-66.